Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment

Journal of Clinical Psychopharmacology

Volumn 20, Issue 6, 2000, Pages 636-644

  Walker, John R ^a,b   Van Ameringen, Michael A ^a   Swinson, Richard ^a   Bowen, Rudradeo C ^a   Chokka, Pratap Rao ^a   Goldner, Elliot ^a   Johnston, David C ^a   Lavallie, Yvon Jacques ^a   Nandy, Saibal ^a   Pecknold, John C ^a   Hadrava, Vratislav ^a   Lane, Roger M ^a  

^a PFIZER INC   (United States)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SERTRALINE;

ADULT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; RISK ASSESSMENT; SOCIAL PHOBIA; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOBIC DISORDERS; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SURVIVAL ANALYSIS;

EID: 0033695675     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200012000-00009     Document Type: Article

References (37)

1. Social phobia: Epidemiology, recognition and treatment
2. Social phobia in general health care: An unrecognized undertreated disabling disorder
3. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
4. Functional impairment in social phobia
5. How shy is too shy?
6. Advances in behavioral-cognitive therapy of social phobia
7. Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine
8. Phenelzine vs atenolol in social phobia
9. Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin reuptake inhibitor brofaromine. A double-blind placebo-controlled study
10. Treatment of social phobia with clonazepam and placebo
11. Sertraline in social phobia: A double-blind, placebo-controlled crossover study
12. Psychopharmacological treatment of social phobia: A double-blind, placebo-controlled study with fluvoxamine
13. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized, double-blind, placebo-controlled study
14. Fluvoxamine treatment of social phobia: A double blind, placebo-controlled study
15. A placebo-controlled study of sertraline in generalized social phobia
16. Treatment of generalized social phobia
17. Moclobemide in social phobia: A controlled dose response trial
18. Placebo-controlled trial of moclobemide in social phobia
19. Brief standard self-rating for phobic patients
20. The Brief Social Phobia Scale
21. The Brief Social Phobia Scale: A psychometric evaluation
22. Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol
23. An empirically derived inventory to measure social fears and anxiety: The Social Phobia and Anxiety Inventory
24. Measurement of social-evaluative anxiety
25. A new depression scale designed to be sensitive to change
26. The Clinical Anxiety Scale: An instrument derived from the Hamilton Anxiety Scale
27. Assessing impairment in patients with panic disorder: The Sheehan Disability Scale
28. Discontinuation of clonazepam in the treatment of social phobia
29. Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind placebo-controlled discontinuation
30. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial
31. A comparison of symptoms following treatment interruption: Evidence from a randomized, double-blind trial with fluoxetine, sertraline, and paroxetine
32. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs)
33. Sertraline and quality of life across mood and anxiety disorders